

Livoseltamab

Chemical Properties

CAS No. : 2408319-25-3

Formula:

Molecular Weight:

Storage: Store at low temperature
Store at -20°C

Actual storage temperature shall be subject to the COA.

Biological Description

Description	Livoseltamab (REGN5458) is a fully human BCMA x CD3 bispecific T-cell engaging antibody. This product simultaneously binds to B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T cells, inducing T-cell directed killing of tumor cells. It plays a significant role in the research of treatment mechanisms for relapsed/refractory multiple myeloma.
In vitro	In vitro assays, Livoseltamab (0.1-10 nM) effectively activates NFAT signaling and increases the expression of CD25 in effector cells, demonstrating potent cytotoxicity against BCMA-expressing human plasma cells and multiple myeloma cell lines such as NCI-H929 and MOLP-8 [2].
In vivo	In pharmacological studies using NCI-H929 or MOLP-8 xenograft mouse models, intravenous administration of Livoseltamab (0.4-4 mg/kg, twice a week for 7 doses) demonstrated robust anti-tumor activity by significantly inhibiting tumor volume growth in a dose-dependent manner, confirming its efficacy in promoting T-cell mediated clearance of myeloma cells in vivo [2].

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481